Responsibility

What we do to support Lung Cancer Awareness Month

November is Lung Cancer Awareness Month. A month dedicated to those affected and to raising public awareness about the causes, early detection and prevention of the disease. Did you know lung cancer is the leading cause of cancer death worldwide? At MSD, we are committed to fighting lung cancer and improving cancer care. Learn how we support Lung Cancer Awareness Month.

24.10.2023

Share this article

.st0{fill:#00857C;}

Lung cancer awareness

In Switzerland around 4,800 people are diagnosed with lung cancer every year and about 3,300 die from it. Almost all new patients are over 50 years of age at the time of diagnosis. Most lung cancers do not cause any symptoms until they have spread. Therefore, they are often diagnosed at a late stage. If the cancer has already spread outside the lungs, the prognosis for patients is very poor. But because of new effective treatments, this is changing. Many people think a lung cancer diagnosis is a death sentence. However, over the past decade, new advancements have been made, which have led to more survivors and more hope for those facing the disease.

At MSD, we show solidarity for those affected and continue to push for progress in cancer care.”

Despite how common lung cancer is, there are still many misconceptions about the disease. That’s why we support various initiatives to raise awareness!

Website for lung cancer patients

The website on the MSD Patient Portal provides detailed information on the main types of lung cancer, diagnosis and treatment options, answers to the most frequent questions and information on where patients can get advice and support.
In addition, lung cancer patients can download various checklists with questions to help them prepare for their next doctor’s appointment.

Visit the MSD Patient Portal (in German, French, Italian)

Image: lung cancer website in the MSD patient portal
Image: public event on lung cancer

Public event about lung cancer

As part of Lung Cancer Awareness Month in November, we would like to draw attention to the topic of lung cancer, raise awareness of the disease and highlight the importance of early detection.

In this respect, we are co-sponsoring a public event on November 2, 2023 in Zurich.

You are cordially invited to attend.

Find out more (in German)

Online lung check

In many cases, lung cancer is only discovered at an advanced stage. This may be because the signs and symptoms are also typical of other diseases and are not immediately associated with lung cancer.

Do you know the symptoms of lung cancer? Do you have symptoms that you should have checked out by a doctor?

Take the online lung check! (in German, French and Italian)

Image: online lung check

About our clinical research in Oncology

Did you know that MSD operates one of the world’s largest and fastest growing clinical research programs in oncology? It currently includes more than 1,600 clinical trials. Switzerland is part of this research program. Our team currently coordinates 34 clinical trials in different tumor types (as of 10/2023). MSD is also one of the leading companies in the research of vaccines against preventable diseases, such as cervical cancer and other HPV-related cancers. In Switzerland, we collaborate with various partners to advance innovative solutions in cancer treatment. In recent years, we have made an important contribution to improving treatment options for cancer patients.

Find out more about our work here.


CH-NON-01949, 10/2023

Hero Image
Our commitment

Pulmonary hypertension

Every single life motivates us, day after day, to give our best.

Pulmonary hypertension is a chronic disease that can be life-threatening if left untreated. At MSD, we are committed to people who are affected by this disease.

Pulmonary hypertension (PH) is a chronic disease characterised by increased blood pressure in the pulmonary circulation. It may lead to a significant impairment of physical capacity and can be life-threatening if left untreated. There are various treatment options that aim to alleviate symptoms, stop progression of the disease and maintain the highest possible quality of life.

Find out more

Our commitment in the area of pulmonary hypertension

For over
5

years committed to improving the lives of patients in Switzerland

In the year
2013

introduction of the first soluble guanylate cyclase (sGC) stimulator for PH in Switzerland

Active since
2016

in longstanding partnerships and projects

Our partnerships and projects

Collaboration with the Schweizerische Gesellschaft für Pulmonale Hypertonie [Swiss Society for Pulmonary Hypertension] (SGPH)

The SGPH is panel of experts that for more than 20 years has bundled all findings about pulmonary hypertension into one efficient network. We have supported the SGPH for years in different projects and initiatives.

Cooperation with patient organisations

We have been involved for years in collaborative partnerships with patient organisations and the Swiss PH Society for people with pulmonary hypertension.

Continuing education events and conferences

MSD regularly takes part in the conference of the Schweizerische Gesellschaft für Pneumologie [Swiss Society for Pulmonology] (SGP) and supports continuing education events for physicians in order to help clarify pulmonary hypertension and its treatment.

Clinical Research

For almost 130 years, we have conducted research worldwide to contribute to better health for our society with our medications and vaccines, for today and future generations. In Switzerland, MSD is currently conducting 42 clinical studies in different areas of therapy (as of 10/2023).

Find out more

Information and education

Especially in November, during Pulmonary Hypertension Awareness Month, and on 5 May, World Pulmonary Hypertension Day, we raise awareness of the disease and the importance of early detection among the general public.

frau lächelt in die kamera

"The sooner pulmonary hypertension is diagnosed and treated, the sooner a patient can benefit from an improvement in the quality of his or her life. With our commitment, we wish to contribute to the clarification and early detection of the disease".

Claudia Kimmich

Senior Customer Engagement Specialist Pulmonary Hypertension, MSD Schweiz

CH-NON-01417, 09/2023